Skip to main content

Advertisement

Figure 2 | Journal of Translational Medicine

Figure 2

From: Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

Figure 2

Discrepancy between SLC22A18 promoter methylation and protein expression. Representative samples for SLC22A18 promoter methylation and protein expression (1, 2) as well as lack of promoter methylation and protein expression (3, 4) are shown. (A) Polyacrylamide gel showing amplification products of unmethylated and methylated DNA sequences by MSP. Positive controls for unmethylated (pcu) and methylated (pcm) sequences were shown. (B) Western blot analysis for the corresponding cases.

Back to article page